“The CTMAV 547 vaccine batch are shown to have normal toxicity and sterility levels, and there are no connections between the vaccine and any post immunization incidents.”
BPOM’s findings determined that the CTMAV 547 vaccine batch, which came to Indonesia on April 26 via the Covax Facility and World Health Organization [WHO], can be used to immunize the Indonesian public.
The National Commission for Post Immunization Incidents or Komnas KIPI also ruled that Covid-19 vaccines from AstraZeneca have not killed anyone in Indonesia.
“Those who died after they received a Covid-19 vaccination did not die of the vaccine, but from other [health] factors,” said the Commission.
The World Health Organization [WHO] and EMA or European Medical Association review also dispelled concerns about the AstraZeneca vaccine causing blood clots.
“Blood clots occurred in in 222 cases out of 34 million doses [of the AstraZeneca vaccine] or 0.00065 percent,” the report said. “On the other hand, blood clots from Covid-19 occurred in 165 thousand cases out of every one million people [who were infected], or 16.5 percent.”
Indonesia received the CTMAV 547 batch on April 26, 2021 through the Covax Program/WHO initiative. The batch, which numbered 448,480 doses, is part of the 3,852,000 that Indonesia is set to receive in stages.
Indonesian Counterterrorist Police Nab 10 Suspected Terrorists in Papua